标题/作者	年份
Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review J Fisher, N Zeitouni, W Fan, FH Samie Journal of the American Academy of Dermatology 82 (6), 1490-1500	2020
Liver transplantation for hepatocellular carcinoma: management after the transplant EC Verna, YA Patel, A Aggarwal, AP Desai, C Frenette, AA Pillai, R Salgia, ... American Journal of Transplantation 20 (2), 333-347	2020
Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? MF Nordness, S Hamel, CM Godfrey, C Shi, DB Johnson, LW Goff, ... American Journal of Transplantation 20 (3), 879-883	2020
Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? P De Bruyn, D Van Gestel, P Ost, V Kruse, L Brochez, H Van Vlierberghe, ... Current opinion in oncology 31 (2), 54-64	2019
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors E De Martin, JM Michot, O Rosmorduc, C Guettier, D Samuel JHEP Reports 2 (6), 100170	2020
Systemic treatment of HCC in special populations L Rimassa, N Personeni, C Czauderna, F Foerster, P Galle Journal of hepatology 74 (4), 931-943	2021
Immunotherapy as a downstaging therapy for liver transplantation B Schwacha‐Eipper, I Minciuna, V Banz, JF Dufour Hepatology 72 (4), 1488-1490	2020
Emerging immunotherapy for HCC: A guide for hepatologists F Foerster, SJ Gairing, SI Ilyas, PR Galle Hepatology 75 (6), 1604-1626	2022
Role of locoregional therapies in the wake of systemic therapy DH Palmer, K Malagari, LM Kulik Journal of hepatology 72 (2), 277-287	2020
Liver damage related to immune checkpoint inhibitors N Nishida, M Kudo Hepatology international 13, 248-252	2019
The current landscape of clinical trials for systemic treatment of HCC F Foerster, PR Galle Cancers 13 (8), 1962	2021
Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review Z Qiao, Z Zhang, Z Lv, H Tong, Z Xi, H Wu, X Chen, L Xia, H Feng, ... Frontiers in Immunology 12, 653437	2021
Transplant rejections associated with immune checkpoint inhibitors: a pharmacovigilance study and systematic literature review LS Nguyen, S Ortuno, B Lebrun-Vignes, DB Johnson, JJ Moslehi, A Hertig, ... European Journal of Cancer 148, 36-47	2021
Liver graft rejection following immune checkpoint inhibitors treatment: a review B Hu, XB Yang, XT Sang Medical Oncology 36 (11), 94	2019
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma Korean Liver Cancer Association Korean Journal of Radiology 23 (12), 1126	2022
The role of immunotherapy in hepatocellular carcinoma: a systematic review and pooled analysis of 2,402 patients IA Ziogas, AP Evangeliou, D Giannis, MH Hayat, KS Mylonas, S Tohme, ... The oncologist 26 (6), e1036-e1049	2021
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma LA Huppert, JD Gordan, RK Kelley Clinical Liver Disease 15 (2), 53	2020
Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study RP Carroll, M Boyer, V Gebski, B Hockley, JK Johnston, S Kireta, H Tan, ... The Lancet Oncology 23 (8), 1078-1086	2022
Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma T Zhang, L Zhang, Y Xu, X Lu, H Zhao, H Yang, X Sang American journal of cancer research 10 (6), 1658	2020
Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation L Zhuang, HB Mou, LF Yu, HK Zhu, Z Yang, Q Liao, SS Zheng Hepatobiliary & pancreatic diseases international: HBPD INT 19 (1), 91-93	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。